Four Years' Experience with Dapsone as Prophylaxis Against Leprosy

Malaria, leprosy and dapsone.

Although the preventive action of dapsone against P. falciparum malaria was known for many years, there was no report about the incidence of P. falciparum malaria in leprosy patients treated with dapsone, especially from areas of Southeast Asia where both leprosy and malaria are endemic. Therefore, two clinic-based malaria surveys were undertaken at a gap of 12 years, comprising 506 lepromatous...

Rifampicin for lepromatous leprosy: nine years' experience.

Over 100 patients with lepromatous leprosy were treated with rifampicin in a series of pilot, uncontrolled, and controlled trials in 1968-77. The rapid bactericidal effect of rifampicin on Mycobacterium leprae was confirmed. Clinical improvement became apparent sometimes as early as 14 days after the start of treatment. Nevertheless, a few persisting viable M leprae were detected as long as fiv...

Five years' experience with thalidomide treatment in leprosy reaction.

Dapsone agranulocytosis in a leprosy patient.

Dapsone-induced agranulocytosis is a rare adverse effect. There are various reports of agranulocytosis in patients treated with dapsone for malaria prophylaxis and other dermatological diseases. However, this adverse reaction in leprosy is not often encountered. We describe agranulocytosis in a young patient who was taking dapsone (100 mg) for borderline-tuberculoid leprosy in a rural environment.

Low dose dapsone therapy in lepromatous leprosy.

U n der the conditions of this s tudy, dapsone in d oses of 5 mg and 10 mg daily when ad ministered to p atients with lepromat ous leprosy is an ineffe ctive therapy in terms of killing and elimin ation of My co. leprae from human skin and b one marrow . A real danger of facili tating the emergence of resistant bacilli exists . Therefore , un til there is more evidence from long term therapeuti...